Now showing items 1-5 of 5
Targeted therapy of solid tumors by monoclonal antibody specific to epidermal growth factor receptor.
Tumor growth and progression depends largely on the activity of cell membrane receptors like epidermal growth factor receptor (EGFR) that plays a pivotal role in the progression and invasion of different solid tumors. As ...
Impacts of anti-EGFR monoclonal antibody in prostate cancer PC3 cells.
Epidermal growth factor receptor (EGFR) network appears to be a rich target for prostate cancer. Thus, in this current investigation, to pursue our newly developed anti-EGFR monoclonal antibody (mAb) in prostate cancer, ...
Targeting cytokines: production and characterization of anti-TNF-? scFvs by phage display technology.
The antibody display technology (ADT) such as phage display (PD) has substantially improved the production of monoclonal antibodies (mAbs) and Ab fragments through bypassing several limitations associated with the traditional ...
Development and characterization of monoclonal antibodies against human epidermal growth factor receptor in Balb/c mice
For production of monoclonal antibody (mAb) against human epidermal growth factor receptor (EGFR), first, five female Balb/c mice 6 to 8 weeks old were immunized against A431 tumoral cells that express more EGFR on its ...
Target therapy of cancer: Implementation of monoclonal antibodies and nanobodies
In the past decades, the mainstay of systemic therapy for solid and haematological malignancies was chemotherapy; nevertheless this modality has the drawbacks such as drug resistance and eliciting sever cytotoxicity in the ...